In an ongoing phase 2 trial in prostate cancer, the effect of combining an Src inhibitor with an AR inhibitor versus an AR inhibitor alone on the development of EMT in prostate cancer was compared, but no definitive results have been published (125). Here, AR is linked to prostate carcinoma.